Mergers & Acquisitions
Apr. 13, 2004
Amgen Agrees to Acquire Rest of Tularik
For Amgen Inc., the world's largest biotechnology firm, owning just part of Tularik Inc. is no longer enough. A year after buying a 21-percent stake in Tularik, Amgen has agreed to buy the rest of the company to expand its clinical pipeline and research capabilities. Amgen, based in Thousand Oaks, announced last month that it will pay $1.3 billion in stock for the purchase.
A year after buying a 21-percent stake in Tularik, Amgen has agreed to buy the rest of the company to expand its clinical pipeline and research capabilities. Amgen, based in Thousand Oaks, announced last mont...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In